Trial Profile

A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 22 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Soquelitinib (Primary) ; Antineoplastics; Belinostat; Pralatrexate
Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Registrational; Therapeutic Use
Sponsors Corvus Pharmaceuticals

17 Apr 2025 Planned End Date changed from 1 Sep 2027 to 1 Jul 2028.
17 Apr 2025 Planned primary completion date changed from 1 Feb 2026 to 1 Nov 2026.
10 Sep 2024 According to a Corvus Pharmaceuticals media release, Swaminathan P. Iyer is the principal investigator of the study .

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com